A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 99
Updated:4/21/2016
Start Date:April 2012
End Date:June 2016
Contact:AstraZeneca Clinical Study Information Center
Email:information.center@astrazeneca.com
Phone:1-877-240-9479

Use our guide to learn which trials are right for you!

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Adult Subjects With Advanced Solid Tumors

This is a first-time-in-human, Phase 1, multicenter, open-label, single-arm, dose-escalation
(3+3) study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity
of MEDI0639.

This is a first-time-in-human, Phase 1, multicenter, open-label, single-arm, dose-escalation
(3+3) study to evaluate the safety, tolerability, antitumor activity, PK, and immunogenicity
of MEDI0639 in adult subjects with advanced solid tumors refractory to standard therapy or
for which no standard therapy exist. Up to 63 subjects will be enrolled at approximately 3
to 5 study centers in North America.

Inclusion Criteria:

- Histologically or cytologically confirmed solid tumors that are refractory to
standard therapy or for which no standard therapy exist

- Age ≥ 18 years

- ECOG Performance Status of 0 or 1

- LVEF (measured by Echocardiogram) > 50%

- No gastrointestinal bleeding within 1 year of study entry.

- Adequate organ and marrow function:

- Hemoglobin ≥ 10g/dL

- Absolute Neutrophil Count ≥ 1500/mm3

- Platelet Count ≥ 100,000/mm3

- AST & ALT ≤ 2.5 x ULN

- Bilirubin ≤ 1.5 x ULN

- Cr Cl ≥ 50 mL/min (as determined by the Cockcroft-Gault equation or by 24-hour
urine collection)

- Prior therapy against VEGF or VEGFRs including, but not limited to bevacizumab,
sunitinib, sorafenib, pazopanib, motesanib (AMG706), or cediranib (AZD2171), is
permitted so long as the agent does not have any known activity against DLL4 and the
last dose received s at least 6 weeks prior to first dose of MEDI0639.

- Life expectancy ≥ 12 weeks

- Females of childbearing potential must be surgically sterile, have a sterile male
partner, be premenarchal or at least 2 years postmenopausal, practice abstinence or
otherwise must use 2 effective methods of contraception from the time of initiation
of investigational product.

- Males, unless surgically sterile, must use 2 effective methods of contraception with
a female partner and must agree to continue using such contraception for 90 days
after the last dose of MEDI0639

Exclusion Criteria:

- Concurrent enrollment in another investigational clinical study

- Receipt of any investigational anticancer therapy within 4 weeks prior to the first
dose of MEDI0639 or in the case of monoclonal antibodies, 6 weeks prior to the first
dose of MEDI0639

- Concurrent or previous treatment with inhibitors of DLL4

- Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal
therapy for cancer treatment

- Known bleeding diathesis, esophageal varices, or angioplasty

- Pulmonary hemorrhage or gross hemoptysis within 12 months

- Known arterial or venous thrombosis or pulmonary embolism within 2 years

- Concurrent use of systemic low molecular weight heparin or low dose warfarin

- Presence of brain metastases

- Cerebrovascular accident or transient ischemic attack within 2 years

- Cardiovascular events, such as myocardial infarction, unstable/severe angina,
coronary/peripheral artery bypass graft, unstable cardiac arrhythmia requiring
medication, congestive heart failure (NYHA > class II), within 2 years

- Tumors with squamous cell histology

- Major surgical procedure within 90 days

- Pregnancy or lactation

- Known HIV positive or Hepatitis A, B, or C infection
We found this trial at
11
sites
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
?
mi
from
New Haven, CT
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Tacoma, WA
Click here to add this to my saved trials